MedPath

Japanese study to evaluate the utility of eribulin dose and schedule in treatment for advanced breast cancer patients

Not Applicable
Completed
Conditions
breast cancer
Registration Number
JPRN-UMIN000008491
Lead Sponsor
PO Advanced Clinical Reserch Organization
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

(1) infectious disease with fever (2) heart failure with clinically problem. significant interstitial pneumonia or pulmonary fibrosis by chest radiograph (3) pleural effusion, peritoneal effusion (4) presence of the active other malignancies (5) poorly controlled diabetes mellitus(6) brain metastasis with symptom (7) pregnant or nursing women (8) physician judged improper to entry this trial

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath